RxDoctor Payments Data

Tras Pfeifer, PA

Physician Assistant · Lander, WYNPI 1477224608

Payments from drug & device makers

$341in general payments, 2019–2025

Across 15 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$87
  • GSK$81
  • AstraZeneca$55
  • Organon$43
  • Novo Nordisk$28
  • AbbVie$20
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$341100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Dexcom, Inc.1$87
GSK4$81
AstraZeneca3$55
Organon3$43
Novo Nordisk1$28
AbbVie1$20
Lilly USA, LLC1$15
Bayer1$13

How this compares

$341 in reported general payments places this provider in the 65th percentile of 203 physician assistant providers in Wyoming.

See all physician assistant providers in Wyoming

Medicare billing

Part B allowed, 2024
$113,553
Medicare patients
312
Services billed
9,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$31,053
OzempicSemaglutide32$29,170
EliquisApixaban33$28,258
TrulicityDulaglutide29$27,022
MounjaroTirzepatide13$18,990
FarxigaDapagliflozin Propanediol17$15,954
Breo ElliptaFluticasone/Vilanterol11$6,703
XareltoRivaroxaban12$6,667
Gabapentin74$2,095
Potassium Chloride95$1,725
Propranolol Hcl ErPropranolol Hcl12$1,679
Tizanidine Hcl18$1,503
SynthroidLevothyroxine Sodium12$1,372
Armour ThyroidThyroid,pork20$1,368
Levothyroxine Sodium114$1,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$15$46,01242 claims
GSKTrelegy Ellipta, Breo Ellipta$81$37,75647 claims
Novo NordiskOzempic$28$29,17032 claims
AstraZenecaFarxiga$55$15,95417 claims
AbbVieSynthroid, Armour Thyroid$20$2,74032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 203 physician assistant providers in Wyoming.

Other physician assistant in Lander

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →